UNSPSC 51422312: Methylprednisolone

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H30O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X4W7ZR7023, chemically known as 1,4-butanedioic acid (succinic acid) but generally known as methylprednisolone, which bears US NIH Compound Identifier 1110. European Medicines Agency schedules Methylprednisolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08872MIG.

UNSPSC 51422312 Methylprednisolone is a Commodity code that sits at the lowest tier of the UN taxonomy for pharmaceutical products. The recent opportunities tagged under this code show a substantial mismatch: the two most recent state and local solicitations involve naloxone procurement and therapeutic pharmacy initiative sourcing strategy, neither of which concerns methylprednisolone (a corticosteroid). The code appears to receive little relevant recent activity aligned with its nominal scope. State and local governments buying methylprednisolone typically do so through health departments, corrections agencies, and managed Medicaid programs as part of broader pharmaceutical supply contracts, but the current opportunity pipeline does not surface dedicated methylprednisolone solicitations.

The two posted opportunities underscore this disconnect. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) for naloxone and drug deactivation systems with quarterly deliveries, while the Texas Health and Human Services Commission posted RFI HHS0017013 (due April 3, 2026) to explore direct-to-manufacturer prescription fulfillment models. Neither procurement targets methylprednisolone as a line item or primary focus. Without recent opportunities explicitly tied to methylprednisolone sourcing, the code does not present an active pursuit window at this time.